Mark Levine
Concepts (436)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ascorbic Acid | 50 | 2025 | 184 | 11.270 |
Why?
| | Erythrocyte Deformability | 4 | 2024 | 23 | 2.080 |
Why?
| | Erythrocytes | 7 | 2024 | 748 | 1.790 |
Why?
| | Vitamins | 8 | 2023 | 182 | 1.650 |
Why?
| | Vitamin E | 4 | 2020 | 125 | 1.580 |
Why?
| | Anemia, Sickle Cell | 4 | 2023 | 318 | 1.450 |
Why?
| | Antioxidants | 8 | 2020 | 550 | 1.230 |
Why?
| | Dehydroascorbic Acid | 5 | 2025 | 6 | 1.220 |
Why?
| | Organic Anion Transporters, Sodium-Dependent | 8 | 2010 | 14 | 1.010 |
Why?
| | Ascorbic Acid Deficiency | 2 | 2023 | 10 | 0.980 |
Why?
| | Symporters | 8 | 2010 | 48 | 0.980 |
Why?
| | Hydrogen Peroxide | 7 | 2024 | 335 | 0.890 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 1963 | 0.850 |
Why?
| | Antineoplastic Agents | 6 | 2020 | 2214 | 0.840 |
Why?
| | Sodium-Coupled Vitamin C Transporters | 9 | 2016 | 9 | 0.810 |
Why?
| | Osmotic Fragility | 3 | 2024 | 12 | 0.810 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 53 | 0.800 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 104 | 0.790 |
Why?
| | Fabry Disease | 1 | 2023 | 2 | 0.780 |
Why?
| | Pancreatic Neoplasms | 5 | 2024 | 928 | 0.730 |
Why?
| | Quarantine | 2 | 2021 | 31 | 0.710 |
Why?
| | Contact Tracing | 2 | 2021 | 26 | 0.700 |
Why?
| | Prodrugs | 3 | 2024 | 52 | 0.690 |
Why?
| | Glucose Transporter Type 2 | 3 | 2013 | 16 | 0.680 |
Why?
| | Glucose | 8 | 2022 | 1048 | 0.680 |
Why?
| | Neoplasms | 8 | 2022 | 2906 | 0.650 |
Why?
| | Glucose Transport Proteins, Facilitative | 4 | 2017 | 16 | 0.640 |
Why?
| | Thiamine | 4 | 2021 | 19 | 0.620 |
Why?
| | Hydrocortisone | 5 | 2021 | 298 | 0.580 |
Why?
| | Tobacco Products | 1 | 2020 | 84 | 0.580 |
Why?
| | Dietary Supplements | 2 | 2016 | 583 | 0.580 |
Why?
| | Kidney | 4 | 2023 | 1497 | 0.580 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2024 | 293 | 0.580 |
Why?
| | Oxidation-Reduction | 5 | 2025 | 1067 | 0.560 |
Why?
| | Diabetic Nephropathies | 1 | 2022 | 322 | 0.560 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2020 | 110 | 0.550 |
Why?
| | Vitamin B Complex | 2 | 2020 | 39 | 0.530 |
Why?
| | Dietary Fats | 1 | 2019 | 308 | 0.520 |
Why?
| | Fetal Hemoglobin | 1 | 2017 | 8 | 0.520 |
Why?
| | Hemoglobin, Sickle | 1 | 2017 | 20 | 0.510 |
Why?
| | Diabetes Mellitus | 2 | 2024 | 1097 | 0.510 |
Why?
| | Fatty Liver | 1 | 2020 | 253 | 0.510 |
Why?
| | Humans | 68 | 2025 | 145475 | 0.500 |
Why?
| | Scurvy | 2 | 2022 | 17 | 0.480 |
Why?
| | Gelatin | 1 | 2016 | 56 | 0.480 |
Why?
| | Stromal Cells | 1 | 2016 | 121 | 0.480 |
Why?
| | Embryo, Mammalian | 1 | 2016 | 234 | 0.470 |
Why?
| | Biological Transport | 6 | 2017 | 424 | 0.450 |
Why?
| | Iron | 2 | 2020 | 357 | 0.450 |
Why?
| | Mice | 22 | 2024 | 18329 | 0.440 |
Why?
| | Monosaccharide Transport Proteins | 3 | 2004 | 56 | 0.430 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2024 | 934 | 0.430 |
Why?
| | Melanoma, Experimental | 1 | 2015 | 109 | 0.430 |
Why?
| | Complementary Therapies | 2 | 2017 | 95 | 0.410 |
Why?
| | Flavonoids | 2 | 2006 | 85 | 0.410 |
Why?
| | Administration, Intravenous | 4 | 2024 | 172 | 0.410 |
Why?
| | Vermont | 4 | 2021 | 13 | 0.400 |
Why?
| | HIV Infections | 2 | 2023 | 3194 | 0.390 |
Why?
| | Sepsis | 4 | 2021 | 664 | 0.390 |
Why?
| | Animals | 29 | 2024 | 38030 | 0.390 |
Why?
| | Mice, Knockout | 7 | 2017 | 3124 | 0.380 |
Why?
| | Cross-Sectional Studies | 5 | 2024 | 5905 | 0.360 |
Why?
| | Ethics, Medical | 3 | 2021 | 90 | 0.360 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2016 | 910 | 0.350 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2012 | 592 | 0.350 |
Why?
| | Fructose | 3 | 2013 | 132 | 0.330 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 279 | 0.330 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2588 | 0.320 |
Why?
| | Male | 25 | 2024 | 72843 | 0.320 |
Why?
| | Perinatal Mortality | 1 | 2010 | 23 | 0.310 |
Why?
| | Female | 30 | 2024 | 78845 | 0.310 |
Why?
| | Intestinal Mucosa | 2 | 2013 | 675 | 0.290 |
Why?
| | Neoplasm Metastasis | 3 | 2024 | 688 | 0.270 |
Why?
| | Kinetics | 4 | 2020 | 1567 | 0.270 |
Why?
| | Oxidants | 1 | 2008 | 99 | 0.270 |
Why?
| | Capital Punishment | 1 | 2008 | 4 | 0.270 |
Why?
| | Hyperaldosteronism | 1 | 2007 | 12 | 0.260 |
Why?
| | Extracellular Fluid | 1 | 2007 | 38 | 0.250 |
Why?
| | Adrenal Glands | 1 | 2007 | 76 | 0.250 |
Why?
| | Anti-Inflammatory Agents | 2 | 2021 | 477 | 0.250 |
Why?
| | Oocytes | 5 | 2013 | 185 | 0.250 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2007 | 147 | 0.250 |
Why?
| | Physician's Role | 2 | 2008 | 224 | 0.250 |
Why?
| | Adult | 13 | 2024 | 40777 | 0.240 |
Why?
| | Infusions, Intravenous | 4 | 2022 | 428 | 0.240 |
Why?
| | Health Care Reform | 1 | 2007 | 109 | 0.240 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2012 | 2028 | 0.240 |
Why?
| | Apoptosis | 4 | 2020 | 2440 | 0.230 |
Why?
| | Double-Blind Method | 4 | 2024 | 2062 | 0.230 |
Why?
| | Middle Aged | 12 | 2024 | 36215 | 0.230 |
Why?
| | Consensus | 1 | 2007 | 477 | 0.220 |
Why?
| | Rats | 6 | 2016 | 5584 | 0.220 |
Why?
| | Sodium | 2 | 2004 | 198 | 0.210 |
Why?
| | Lymphoma, B-Cell | 1 | 2006 | 140 | 0.210 |
Why?
| | Reactive Oxygen Species | 3 | 2020 | 611 | 0.210 |
Why?
| | Quercetin | 3 | 2013 | 19 | 0.200 |
Why?
| | Aged | 8 | 2024 | 26153 | 0.200 |
Why?
| | Carcinoma, Renal Cell | 1 | 2006 | 230 | 0.200 |
Why?
| | Public Policy | 2 | 2021 | 80 | 0.200 |
Why?
| | Erythrocytes, Abnormal | 1 | 2023 | 14 | 0.190 |
Why?
| | Mustelidae | 1 | 2022 | 2 | 0.190 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2006 | 258 | 0.190 |
Why?
| | Deoxycytidine | 3 | 2017 | 220 | 0.190 |
Why?
| | Lymphoma | 2 | 2020 | 237 | 0.180 |
Why?
| | Diabetic Angiopathies | 1 | 2024 | 264 | 0.180 |
Why?
| | Sample Size | 2 | 2019 | 121 | 0.180 |
Why?
| | Hep G2 Cells | 2 | 2020 | 73 | 0.180 |
Why?
| | Actins | 1 | 2024 | 425 | 0.180 |
Why?
| | HIV | 1 | 2023 | 251 | 0.180 |
Why?
| | Physicians | 2 | 2021 | 955 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 362 | 0.180 |
Why?
| | Kidney Neoplasms | 1 | 2006 | 413 | 0.170 |
Why?
| | Flow Cytometry | 1 | 2025 | 1162 | 0.170 |
Why?
| | Xenopus laevis | 4 | 2006 | 104 | 0.170 |
Why?
| | Sleep Medicine Specialty | 1 | 2021 | 10 | 0.170 |
Why?
| | Blood Platelets | 1 | 2024 | 379 | 0.170 |
Why?
| | Iron, Dietary | 1 | 2021 | 23 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2158 | 0.160 |
Why?
| | Holocaust | 1 | 2021 | 16 | 0.160 |
Why?
| | Absorption | 2 | 2011 | 60 | 0.160 |
Why?
| | Bioethics | 1 | 2021 | 25 | 0.160 |
Why?
| | DNA Damage | 3 | 2020 | 437 | 0.160 |
Why?
| | World Health Organization | 1 | 2020 | 104 | 0.160 |
Why?
| | Students, Health Occupations | 1 | 2021 | 37 | 0.160 |
Why?
| | Anesthesiologists | 1 | 2021 | 68 | 0.160 |
Why?
| | Masks | 1 | 2021 | 70 | 0.160 |
Why?
| | Mice, Nude | 4 | 2024 | 679 | 0.150 |
Why?
| | alpha-Tocopherol | 1 | 2020 | 32 | 0.150 |
Why?
| | Cell Line, Tumor | 6 | 2024 | 3542 | 0.150 |
Why?
| | Housing | 1 | 2021 | 142 | 0.150 |
Why?
| | Succinate Dehydrogenase | 1 | 2020 | 65 | 0.150 |
Why?
| | Drug Synergism | 4 | 2020 | 354 | 0.150 |
Why?
| | Cell Death | 2 | 2013 | 382 | 0.150 |
Why?
| | Tobacco Use | 1 | 2020 | 62 | 0.150 |
Why?
| | Public Health Practice | 1 | 2020 | 63 | 0.150 |
Why?
| | Liver | 3 | 2020 | 1896 | 0.150 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2524 | 0.150 |
Why?
| | Pheochromocytoma | 1 | 2020 | 67 | 0.150 |
Why?
| | Infection Control | 1 | 2021 | 173 | 0.150 |
Why?
| | Nutrition Policy | 2 | 2009 | 57 | 0.150 |
Why?
| | Young Adult | 4 | 2021 | 14219 | 0.150 |
Why?
| | Proteins | 2 | 2003 | 1023 | 0.150 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 765 | 0.140 |
Why?
| | Deuterium | 1 | 2019 | 100 | 0.140 |
Why?
| | Lyme Disease | 1 | 2019 | 58 | 0.140 |
Why?
| | Hepacivirus | 1 | 2020 | 242 | 0.140 |
Why?
| | Health Services Accessibility | 1 | 2007 | 1101 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2021 | 266 | 0.140 |
Why?
| | Employment | 1 | 2021 | 184 | 0.140 |
Why?
| | DNA Demethylation | 1 | 2018 | 4 | 0.140 |
Why?
| | Biological Availability | 2 | 2013 | 145 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2024 | 3623 | 0.140 |
Why?
| | Lipoproteins | 1 | 2020 | 166 | 0.140 |
Why?
| | Genomics | 2 | 2023 | 825 | 0.140 |
Why?
| | Myocarditis | 1 | 2019 | 102 | 0.140 |
Why?
| | Mixed Function Oxygenases | 1 | 2018 | 43 | 0.140 |
Why?
| | Comorbidity | 1 | 2023 | 1661 | 0.140 |
Why?
| | United States | 11 | 2021 | 16098 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2019 | 1747 | 0.140 |
Why?
| | Universities | 1 | 2021 | 445 | 0.140 |
Why?
| | Meals | 1 | 2019 | 130 | 0.140 |
Why?
| | Anesthesiology | 1 | 2021 | 179 | 0.140 |
Why?
| | Blood Viscosity | 1 | 2018 | 19 | 0.140 |
Why?
| | Oxidative Stress | 3 | 2020 | 1356 | 0.130 |
Why?
| | Administration, Oral | 3 | 2013 | 866 | 0.130 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 2018 | 28 | 0.130 |
Why?
| | Integrative Medicine | 1 | 2018 | 17 | 0.130 |
Why?
| | Drug Administration Schedule | 3 | 2019 | 782 | 0.130 |
Why?
| | Fasting | 1 | 2019 | 279 | 0.130 |
Why?
| | Data Interpretation, Statistical | 1 | 2019 | 368 | 0.130 |
Why?
| | Sugar Acids | 1 | 2017 | 4 | 0.130 |
Why?
| | Hepatitis C | 1 | 2020 | 256 | 0.130 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2020 | 194 | 0.130 |
Why?
| | Antisickling Agents | 1 | 2017 | 7 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 265 | 0.130 |
Why?
| | Erythrocyte Indices | 1 | 2017 | 33 | 0.130 |
Why?
| | Injections, Intravenous | 2 | 2010 | 197 | 0.130 |
Why?
| | Blood Cell Count | 1 | 2017 | 55 | 0.130 |
Why?
| | Hydroxyurea | 1 | 2017 | 34 | 0.130 |
Why?
| | Cross-Over Studies | 1 | 2019 | 608 | 0.130 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 117 | 0.130 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 119 | 0.130 |
Why?
| | Oxidoreductases | 1 | 2017 | 91 | 0.130 |
Why?
| | Drug Therapy, Combination | 4 | 2021 | 1044 | 0.130 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 314 | 0.120 |
Why?
| | Athletes | 1 | 2021 | 424 | 0.120 |
Why?
| | Aged, 80 and over | 2 | 2024 | 8333 | 0.120 |
Why?
| | Research Design | 2 | 2019 | 1137 | 0.120 |
Why?
| | Disease Management | 1 | 2020 | 653 | 0.120 |
Why?
| | Job Application | 1 | 2016 | 17 | 0.120 |
Why?
| | In Situ Hybridization | 1 | 2016 | 318 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2021 | 586 | 0.120 |
Why?
| | Risk Factors | 5 | 2024 | 10885 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2019 | 558 | 0.120 |
Why?
| | Free Radicals | 2 | 2007 | 105 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2021 | 562 | 0.120 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 337 | 0.120 |
Why?
| | Colitis, Ulcerative | 1 | 2017 | 148 | 0.120 |
Why?
| | Respiration, Artificial | 1 | 2021 | 713 | 0.110 |
Why?
| | Stress, Mechanical | 1 | 2018 | 494 | 0.110 |
Why?
| | Molecular Structure | 2 | 2007 | 486 | 0.110 |
Why?
| | Hemolysis | 1 | 2017 | 242 | 0.110 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 119 | 0.110 |
Why?
| | Niacinamide | 1 | 2016 | 104 | 0.110 |
Why?
| | Dacarbazine | 1 | 2015 | 100 | 0.110 |
Why?
| | Prevalence | 1 | 2022 | 2865 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 624 | 0.110 |
Why?
| | Public Health | 1 | 2020 | 572 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1581 | 0.110 |
Why?
| | Lipids | 1 | 2020 | 707 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2016 | 2803 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 977 | 0.110 |
Why?
| | Prognosis | 3 | 2018 | 4316 | 0.110 |
Why?
| | Heparin | 1 | 2016 | 247 | 0.110 |
Why?
| | Medical Oncology | 1 | 2017 | 339 | 0.110 |
Why?
| | Cell Line | 1 | 2020 | 2823 | 0.100 |
Why?
| | Collagen | 1 | 2016 | 457 | 0.100 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2015 | 199 | 0.100 |
Why?
| | Mice, Inbred C57BL | 3 | 2024 | 5983 | 0.100 |
Why?
| | Sleep | 1 | 2021 | 888 | 0.100 |
Why?
| | Crohn Disease | 1 | 2017 | 260 | 0.100 |
Why?
| | Cell Membrane | 1 | 2017 | 707 | 0.100 |
Why?
| | Quality of Life | 2 | 2024 | 3204 | 0.100 |
Why?
| | Stents | 1 | 2018 | 564 | 0.100 |
Why?
| | Blood Transfusion | 1 | 2017 | 409 | 0.100 |
Why?
| | Cloning, Molecular | 2 | 2013 | 538 | 0.100 |
Why?
| | Infusions, Parenteral | 2 | 2017 | 48 | 0.100 |
Why?
| | Phloretin | 1 | 2013 | 2 | 0.100 |
Why?
| | Internal Medicine | 1 | 2016 | 279 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2017 | 2507 | 0.100 |
Why?
| | Time Factors | 2 | 2021 | 7123 | 0.090 |
Why?
| | Amino Acid Motifs | 1 | 2013 | 219 | 0.090 |
Why?
| | Genotype | 1 | 2017 | 1852 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2021 | 11772 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1505 | 0.090 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 372 | 0.090 |
Why?
| | Genetic Variation | 3 | 2008 | 972 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 405 | 0.090 |
Why?
| | Erlotinib Hydrochloride | 1 | 2012 | 72 | 0.090 |
Why?
| | Electrochemical Techniques | 1 | 2012 | 55 | 0.090 |
Why?
| | Adolescent | 3 | 2020 | 22530 | 0.090 |
Why?
| | Venous Thromboembolism | 1 | 2016 | 328 | 0.090 |
Why?
| | Biomedical Research | 1 | 2017 | 717 | 0.080 |
Why?
| | Phosphorylation | 1 | 2015 | 1707 | 0.080 |
Why?
| | Intestine, Small | 2 | 2010 | 167 | 0.080 |
Why?
| | Gene Expression | 1 | 2015 | 1476 | 0.080 |
Why?
| | Anticoagulants | 1 | 2016 | 748 | 0.080 |
Why?
| | Placebos | 2 | 2008 | 193 | 0.080 |
Why?
| | Quinazolines | 1 | 2012 | 266 | 0.080 |
Why?
| | Disease Progression | 1 | 2018 | 2864 | 0.080 |
Why?
| | Protein Isoforms | 2 | 2024 | 397 | 0.080 |
Why?
| | Internship and Residency | 2 | 2016 | 1267 | 0.080 |
Why?
| | Physician-Patient Relations | 2 | 2021 | 588 | 0.080 |
Why?
| | Histones | 1 | 2015 | 666 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1767 | 0.080 |
Why?
| | Glucose Transporter Type 5 | 2 | 2006 | 4 | 0.070 |
Why?
| | Glutathione Transferase | 1 | 2009 | 92 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2016 | 776 | 0.070 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 208 | 0.070 |
Why?
| | Diet | 2 | 2017 | 1277 | 0.070 |
Why?
| | Pulmonary Embolism | 1 | 2012 | 241 | 0.070 |
Why?
| | Cell Growth Processes | 1 | 2009 | 48 | 0.070 |
Why?
| | Carcinoma | 1 | 2011 | 225 | 0.070 |
Why?
| | Exercise | 2 | 2016 | 2198 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2016 | 4148 | 0.070 |
Why?
| | Phenotype | 1 | 2017 | 3155 | 0.070 |
Why?
| | Survival Analysis | 2 | 2016 | 1374 | 0.070 |
Why?
| | Therapeutic Human Experimentation | 1 | 2008 | 2 | 0.070 |
Why?
| | Ethics, Research | 1 | 2008 | 31 | 0.070 |
Why?
| | Patient Isolation | 1 | 2008 | 20 | 0.070 |
Why?
| | Blood Preservation | 1 | 2012 | 346 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 734 | 0.070 |
Why?
| | Multicenter Studies as Topic | 2 | 2019 | 412 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1471 | 0.070 |
Why?
| | Oxygen | 1 | 2013 | 978 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 640 | 0.060 |
Why?
| | Truth Disclosure | 1 | 2008 | 51 | 0.060 |
Why?
| | Vitamin D Deficiency | 1 | 2009 | 190 | 0.060 |
Why?
| | Animals, Newborn | 1 | 2010 | 891 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1443 | 0.060 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2006 | 11 | 0.060 |
Why?
| | Caco-2 Cells | 1 | 2006 | 79 | 0.060 |
Why?
| | Flavonols | 1 | 2006 | 27 | 0.060 |
Why?
| | Obesity | 1 | 2020 | 3116 | 0.060 |
Why?
| | Trust | 1 | 2008 | 156 | 0.060 |
Why?
| | Microscopy, Confocal | 1 | 2006 | 319 | 0.060 |
Why?
| | Adenoma | 1 | 2008 | 218 | 0.060 |
Why?
| | Pregnancy | 3 | 2022 | 7202 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 614 | 0.050 |
Why?
| | Poly A | 1 | 2004 | 50 | 0.050 |
Why?
| | Phosphoramide Mustards | 1 | 2024 | 3 | 0.050 |
Why?
| | Nitrogen Mustard Compounds | 1 | 2024 | 9 | 0.050 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2004 | 94 | 0.050 |
Why?
| | A549 Cells | 1 | 2024 | 75 | 0.050 |
Why?
| | Actin Cytoskeleton | 1 | 2024 | 103 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2009 | 782 | 0.050 |
Why?
| | Cardiovascular Diseases | 2 | 2009 | 2187 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1061 | 0.050 |
Why?
| | Curriculum | 2 | 2021 | 1070 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2024 | 2129 | 0.050 |
Why?
| | Cytoskeleton | 1 | 2024 | 192 | 0.050 |
Why?
| | Cell Hypoxia | 1 | 2024 | 247 | 0.050 |
Why?
| | L-Gulonolactone Oxidase | 1 | 2022 | 2 | 0.050 |
Why?
| | Transfection | 2 | 2002 | 926 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2010 | 925 | 0.050 |
Why?
| | Prostatic Neoplasms | 1 | 2010 | 978 | 0.050 |
Why?
| | Child | 1 | 2023 | 22707 | 0.050 |
Why?
| | Erythropoiesis | 1 | 2022 | 57 | 0.050 |
Why?
| | Lipid Peroxidation | 1 | 2003 | 167 | 0.050 |
Why?
| | Reference Values | 1 | 2004 | 798 | 0.050 |
Why?
| | Rats, Zucker | 1 | 2002 | 32 | 0.040 |
Why?
| | Fruit | 1 | 2003 | 146 | 0.040 |
Why?
| | Prospective Studies | 3 | 2019 | 8057 | 0.040 |
Why?
| | Vegetables | 1 | 2003 | 161 | 0.040 |
Why?
| | CHO Cells | 1 | 2002 | 169 | 0.040 |
Why?
| | Deoxyglucose | 1 | 2002 | 51 | 0.040 |
Why?
| | Cricetinae | 1 | 2002 | 305 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2022 | 219 | 0.040 |
Why?
| | Area Under Curve | 1 | 2022 | 331 | 0.040 |
Why?
| | Premature Birth | 1 | 2005 | 388 | 0.040 |
Why?
| | Intestinal Absorption | 1 | 2002 | 103 | 0.040 |
Why?
| | Erythrocyte Count | 1 | 2021 | 21 | 0.040 |
Why?
| | Early Termination of Clinical Trials | 1 | 2021 | 18 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2002 | 277 | 0.040 |
Why?
| | Credentialing | 1 | 2021 | 21 | 0.040 |
Why?
| | Humanities | 1 | 2021 | 8 | 0.040 |
Why?
| | Diet Therapy | 1 | 2021 | 36 | 0.040 |
Why?
| | Hematocrit | 1 | 2021 | 108 | 0.040 |
Why?
| | Organ Dysfunction Scores | 1 | 2021 | 55 | 0.040 |
Why?
| | Health Occupations | 1 | 2021 | 36 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2025 | 892 | 0.040 |
Why?
| | Phylogeny | 1 | 2004 | 917 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2007 | 946 | 0.040 |
Why?
| | Morals | 1 | 2021 | 78 | 0.040 |
Why?
| | Lipogenesis | 1 | 2020 | 62 | 0.040 |
Why?
| | Policy | 1 | 2021 | 148 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2021 | 150 | 0.040 |
Why?
| | Spirochaetales | 1 | 2019 | 1 | 0.040 |
Why?
| | Endocardium | 1 | 2019 | 31 | 0.040 |
Why?
| | 5-Methylcytosine | 1 | 2020 | 24 | 0.040 |
Why?
| | Granzymes | 1 | 2020 | 49 | 0.040 |
Why?
| | Borrelia burgdorferi | 1 | 2019 | 21 | 0.040 |
Why?
| | Alleles | 2 | 2017 | 894 | 0.040 |
Why?
| | Heart Block | 1 | 2019 | 41 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 5216 | 0.040 |
Why?
| | Colorectal Neoplasms | 1 | 2008 | 866 | 0.040 |
Why?
| | Models, Biological | 1 | 2006 | 1764 | 0.040 |
Why?
| | Atrioventricular Block | 1 | 2019 | 44 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4560 | 0.040 |
Why?
| | Fibroblasts | 1 | 2004 | 1025 | 0.040 |
Why?
| | Paraganglioma | 1 | 2020 | 64 | 0.040 |
Why?
| | Massachusetts | 1 | 2019 | 180 | 0.040 |
Why?
| | Counseling | 1 | 2002 | 400 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 333 | 0.040 |
Why?
| | Neutrophils | 1 | 2004 | 1124 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2019 | 305 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 956 | 0.040 |
Why?
| | Perioperative Care | 1 | 2021 | 231 | 0.030 |
Why?
| | Teaching | 1 | 2021 | 237 | 0.030 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 271 | 0.030 |
Why?
| | Manitoba | 1 | 2017 | 4 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2020 | 251 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 265 | 0.030 |
Why?
| | Xenopus | 1 | 2017 | 87 | 0.030 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 244 | 0.030 |
Why?
| | Up-Regulation | 1 | 2020 | 847 | 0.030 |
Why?
| | Anesthesia | 1 | 2021 | 256 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 326 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2017 | 335 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1261 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2005 | 1244 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1266 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2010 | 2664 | 0.030 |
Why?
| | Cell Survival | 1 | 2020 | 1100 | 0.030 |
Why?
| | DNA | 1 | 2003 | 1435 | 0.030 |
Why?
| | Electrocardiography | 1 | 2019 | 665 | 0.030 |
Why?
| | Risk Assessment | 2 | 2021 | 3747 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2017 | 886 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 732 | 0.030 |
Why?
| | Health Promotion | 1 | 2002 | 775 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2016 | 171 | 0.030 |
Why?
| | Haplotypes | 2 | 2008 | 499 | 0.030 |
Why?
| | Length of Stay | 1 | 2021 | 1349 | 0.030 |
Why?
| | Immunotherapy | 1 | 2020 | 666 | 0.030 |
Why?
| | Critical Illness | 1 | 2021 | 900 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2019 | 1038 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2020 | 919 | 0.020 |
Why?
| | Precision Medicine | 1 | 2017 | 459 | 0.020 |
Why?
| | Firearms | 1 | 2020 | 436 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2930 | 0.020 |
Why?
| | Clinical Competence | 1 | 2021 | 1243 | 0.020 |
Why?
| | Patient Selection | 1 | 2016 | 738 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2011 | 196 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2010 | 246 | 0.020 |
Why?
| | Brain | 1 | 2002 | 2947 | 0.020 |
Why?
| | Mitochondria | 1 | 2016 | 992 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2010 | 331 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2010 | 450 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2378 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 4075 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2010 | 376 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2021 | 2970 | 0.020 |
Why?
| | Disease Notification | 1 | 2008 | 16 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5423 | 0.020 |
Why?
| | ROC Curve | 1 | 2010 | 617 | 0.020 |
Why?
| | American Medical Association | 1 | 2008 | 19 | 0.020 |
Why?
| | Placebo Effect | 1 | 2008 | 24 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 6013 | 0.020 |
Why?
| | Community Participation | 1 | 2008 | 123 | 0.020 |
Why?
| | Informed Consent | 1 | 2008 | 198 | 0.010 |
Why?
| | Body Weight | 1 | 2010 | 971 | 0.010 |
Why?
| | North Carolina | 1 | 2005 | 129 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2011 | 881 | 0.010 |
Why?
| | Forearm | 1 | 2005 | 141 | 0.010 |
Why?
| | Glucose Clamp Technique | 1 | 2005 | 199 | 0.010 |
Why?
| | Gene Components | 1 | 2004 | 6 | 0.010 |
Why?
| | Base Composition | 1 | 2004 | 82 | 0.010 |
Why?
| | Likelihood Functions | 1 | 2004 | 138 | 0.010 |
Why?
| | Linkage Disequilibrium | 1 | 2004 | 253 | 0.010 |
Why?
| | Species Specificity | 1 | 2004 | 546 | 0.010 |
Why?
| | Genomic Library | 1 | 2002 | 16 | 0.010 |
Why?
| | Restriction Mapping | 1 | 2002 | 81 | 0.010 |
Why?
| | Surveys and Questionnaires | 2 | 2008 | 6066 | 0.010 |
Why?
| | Genes, Essential | 1 | 2002 | 19 | 0.010 |
Why?
| | Blotting, Northern | 1 | 2002 | 203 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 93 | 0.010 |
Why?
| | Vasodilation | 1 | 2005 | 521 | 0.010 |
Why?
| | Models, Genetic | 1 | 2004 | 524 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2002 | 273 | 0.010 |
Why?
| | Testis | 1 | 2002 | 162 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2004 | 777 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2002 | 147 | 0.010 |
Why?
| | Base Sequence | 1 | 2002 | 2170 | 0.010 |
Why?
| | Blood Pressure | 1 | 2005 | 1779 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2883 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 1193 | 0.010 |
Why?
|
|
Levine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|